Decheng Capital LLC
MENLO PARK CA · SEC CIK 0002010850
$7.32亿2026Q2 申报市值
14持仓数
98.1%前十大占比 · 第一大 61.9%
1 / 1新建仓 / 清仓
26Q126Q2
前十大持仓 占组合比例
2026Q2 买入最多 按季末市值估算
TNGX 新建仓+$62.52万
2026Q2 卖出最多 按季末市值估算
RVMD 减仓-$764.72万
NAMS 减仓-$502.15万
KRYS 清仓-$188.57万
RCUS 减仓-$40.20万
2026Q2 持仓明细 点表头排序
导出 CSV 🔒| 代码 | 名称 | 市值 ▼ | 占比 | 股数 | 变动股数 | 变动 | 估算买卖额 | 操作 |
|---|---|---|---|---|---|---|---|---|
| CGON | CG ONCOLOGY INC | $4.53亿 | 61.87% | 6,371,669 | 0 | 0.0% | — | 不变 |
| NUVB | Nuvation Bio Inc. | $1.47亿 | 20.15% | 25,954,439 | 0 | 0.0% | — | 不变 |
| — | AARDVARK THERAPEUTICS INC | $2,256.36万 | 3.08% | 3,917,299 | 0 | 0.0% | — | 不变 |
| ACRS | Aclaris Therapeutics, Inc. | $2,138.08万 | 2.92% | 4,041,736 | 0 | 0.0% | — | 不变 |
| UPB | Upstream Bio Inc. | $1,885.61万 | 2.58% | 2,724,868 | 0 | 0.0% | — | 不变 |
| RCUS | Arcus Biosciences, Inc | $1,432.91万 | 1.96% | 464,779 | -13,040 | -2.7% | -$40.20万 | 减仓 |
| EQ | Equillium Inc. | $1,423.14万 | 1.94% | 4,447,308 | 0 | 0.0% | — | 不变 |
| RVMD | REVOLUTION MEDICINES INC(NSM) | $986.35万 | 1.35% | 52,667 | -40,833 | -43.7% | -$764.72万 | 减仓 |
| — | Lyell Immunopharma, Inc. | $972.33万 | 1.33% | 692,050 | 0 | 0.0% | — | 不变 |
| — | BeyondSpring Inc. | $665.12万 | 0.91% | 3,800,702 | 0 | 0.0% | — | 不变 |
| ZNTL | Zentalis Pharmaceuticals Inc. | $641.81万 | 0.88% | 1,323,327 | 0 | 0.0% | — | 不变 |
| NAMS | NEWAMSTERDAM PHARMA CO NV | $599.47万 | 0.82% | 176,887 | -148,170 | -45.6% | -$502.15万 | 减仓 |
| — | Pyxis Oncology, Inc (formerly Apexigen) | $98.37万 | 0.13% | 326,810 | 0 | 0.0% | — | 不变 |
| TNGX | TANGO THERAPEUTICS INC | $62.52万 | 0.09% | 20,000 | 20,000 | — | $62.52万 | 新建仓 |
| KRYS | KRYSTAL BIOTECH INC | $0 | 0.00% | 0 | -7,300 | -100.0% | -$188.57万 | 清仓 |